Clinical Trial Update: Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating Niagen (nicotinamide riboside) for recovery from persistent cognitive and physical symptoms after COVID-19 has completed and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Niagen®+ (nicotinamide riboside)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Covid19, Sequelae of; Infection | Phase 4 | Status: COMPLETED | Results posted: 2025-06-25